| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.012 | 0.9 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |